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Pharmacogenomics and chemical library screens reveal a novel
SCFSKP2 inhibitor that overcomes Bortezomib resistance in
multiple myeloma
E Malek1,2,10, MAY Abdel-Malek2,3,4,10, S Jagannathan2,3,10, N Vad2,3, R Karns5, AG Jegga5, A Broyl6, M van Duin6, P Sonneveld6,
F Cottini7,8, KC Anderson7,8 and JJ Driscoll2,3,9
While clinical beneﬁt of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged,
dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1–Cullin-1–Skp2 (SCFSkp2)
promotes proteasomal degradation of the cell cycle inhibitor p27 to enhance tumor growth. Increased SKP2 expression and
reduced p27 levels are frequent in human cancers and are associated with therapeutic resistance. SCFSkp2 activity is increased by
the Cullin-1-binding protein Commd1 and the Skp2-binding protein Cks1B. Here we observed higher CUL1, COMMD1 and SKP2
mRNA levels in CD138+ cells isolated from BTZ-resistant MM patients. Higher CUL1, COMMD1, SKP2 and CKS1B mRNA levels in
patient CD138+ cells correlated with decreased progression-free and overall survival. Genetic knockdown of CUL1, COMMD1 or SKP2
disrupted the SCFSkp2 complex, stabilized p27 and increased the number of annexin-V-positive cells after BTZ treatment. Chemical
library screens identiﬁed a novel compound, designated DT204, that reduced Skp2 binding to Cullin-1 and Commd1, and
synergistically enhanced BTZ-induced apoptosis. DT204 co-treatment with BTZ overcame drug resistance and reduced the in vivo
growth of myeloma tumors in murine models with survival beneﬁt. Taken together, the results provide proof of concept for
rationally designed drug combinations that incorporate SCFSkp2 inhibitors to treat BTZ resistant disease.
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INTRODUCTION
Clinical success of the proteasome inhibitor (PI) bortezomib (BTZ)
(Velcade) established the ubiquitin (Ub)+proteasome system as a
key therapeutic target in multiple myeloma (MM).1–3 While the
survival beneﬁt of BTZ has generated new treatment strategies
and brought excitement to the community, signiﬁcant challenges
remain. Many patients do not respond to proteasome inhibitor
therapy and drug resistance nearly uniformly develops, even in
those that initially respond to treatment.4,5 Moreover, individual
patient response to BTZ remains highly variable and the molecular
features responsible for the variability in response remain
undeﬁned.6–9
Speciﬁcity within the Ub+proteasome system relies upon
the selectivity of E3 Ub ligases that maintain proteostasis by
targeting individual proteins for proteasomal degradation.10,11
BTZ blocks the bulk of Ub-dependent protein degradation while
drugs that target an individual E3 Ub ligase are expected to
destabilize a single protein to confer reﬁned selectivity with
reduced adverse toxicities.12,13 The S-phase kinase associated
protein-1 (Skp1) and Cullin-1 bind a multitude of substrate-
binding F-box proteins to form multimeric SCF complexes.14–16
Cell cycle progression is regulated by SCFSkp2, composed of
Skp1, Cullin-1 and Skp2, that mediates ubiquitination of the
cyclin-dependent kinase (CDK) inhibitor (CKI) p27.17,18 Progres-
sion from G1 to S phase is positively regulated by CDK2 and
CDK4, and negatively regulated by p27. SCFSkp2-mediated
ubiquitination marks p27 for degradation that permits the
CDK-dependent transition from a quiescent to proliferative
state. Skp2 binds p27 to facilitate its ubiquitination, and
SKP2 expression contributes to increased p27 turnover
and enhanced proliferation.19–21 Cullin-1 scaffolds Skp1 and
Skp2 and contributes to proliferation by promoting CKI
degradation.22,23 CUL1 overexpression also promotes prolifera-
tion through p27 degradation and high CUL1 expression has
been correlated with reduced survival.24–27 SCF activity is
regulated by accessory proteins, for example, Commd1, that
promotes SCF ubiquitination activity.28,29 COMMD1 overexpres-
sion is associated with poor outcomes in lymphomas.30 p27
ubiquitination also requires the CDK regulator Cks1 and the
Cullin-1-binding protein Rbx1.31
Here publically available databases were used to correlate gene
expression in MM patient tumor cells with clinical responses to
BTZ. A similar approach recently revealed that nicotinamide
phosphoribosyltransferase (Nampt) mRNA expression was higher
in BTZ-resistant patient cells and that Nampt represented a viable
therapeutic target to overcome BTZ resistance.32 We reveal
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signiﬁcantly higher COMMD1 and CUL1 mRNA in patients that did
not respond to BTZ. The ﬁndings prompted us to investigate the
effect of genetic and pharmacologic disruption of the SCFSkp2
complex on BTZ resistance. Using in vitro and in vivo models, we
demonstrate that combining a novel SCFSkp2 inhibitor (DT204)
with BTZ triggered synergistic anti-myeloma activity and over-
came drug resistance.
MATERIALS AND METHODS
Gene expression proﬁle analysis
Cluster version 2.0 was used to analyze data sets GSE9782, GSE2658 and
GSE5900.33–35 Gene expression proﬁles from tumor cells of patients
included in the SUMMIT36 (025), CREST37 phase 2, APEX38 phase 3 trial
(039) and HOVON-65/GMMG-HD4 trials35 were analyzed. A two-step ﬁlter
was used to identify genes differentially regulated in responders vs non-
responders. A true statistical test was applied using t-test or analysis of
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Figure 1. Correlation of the expression of SCFSkp2 components with survival and response to BTZ. (a) Kaplan–Meier PFS curves from MM
patients in APEX trial (039) after BTZ treatment (n= 163) according to gene expression proﬁle arrays generated at Millenium Pharmaceuticals
(Cambridge, MA, USA GSE9782). Probes used were CUL1-207614, SKP2-210567, COMMD1-226024 and CKS1B-201897. PFS was plotted using
median values determined for each probe based on data set GSE9782 obtained from analysis of patient samples. Kaplan–Meier OS curves of
patients treated with BTZ according to CUL1, SKP2, COMMD1 and CKS1B expression above or below median values (GSE9782) are also shown.
(b) Kaplan–Meier OS curves for the expression of either SKP2 or CKS1B based on their expression in patients enrolled in the HOVON65/GMMG-
HD4 study (GSE19784). Expression of the following probe sets was evaluated: CKS1B (201897); COMMD1 (226024); CUL1 (207614 and 238509);
RBX1 (218117); SKP1 (200711 and 200719); and SKP2 (210567 and 203625). Differences in expression in the response categories were assessed
using Kruskal–Wallis analysis to distinguish four categories: complete response/near complete response (CR/nCR); very good partial response
(VGPR); partial response (PR); and minimal response (MR) or worse. The number of patients per category for the BTZ arm was 17
(CR/nCR), 55 (VGPR), 63 (PR) and 11 (MR or worse), and for the control arm was 4 (CR/nCR), 16 (VGPR), 66 (PR) and 43 (MR or worse). Survival
analysis was performed as described using PFS censored for allogeneic transplant and OS.39 Survival analysis was performed with 169 cases in
the BTZ arm and 158 cases in the control arm. (c) Expression of COMMD1, CUL1, SKP2 and CKS1B in tumor cells from patients enrolled in trial
039 that had been treated with BTZ (n= 163) or dexamethasone (DEX; n= 70). Response to therapy was deﬁned in trial 039 and HOVON-65/
GMMG-HD4 using criteria established by the European Group for BMT: http://www.ncbi.nlm.nih.gov/pubmed/9753033?access_num=
9753033&link_type=MED&sso-checked= true&dopt=Abstract. Responders were patients that achieved a complete remission
(CR), very good partial remission (VGPR), partial remission (PR) or minor remission (MR), and non-responders were those patients that
achieved progressive disease (PD), stable disease or minor remission. PD required a 25% increase in paraprotein, whereas MR, PR and
CR required at least a 25%, 50% or 100% decrease, respectively. Baseline correction of the original data set was performed to identify
individual genes differentially expressed in BTZ-non-responders (NRs) relative to BTZ-responders (Rs). Analysis criteria required at least a
ﬁvefold log difference in expression between the NRs and Rs and P-value o0.05. COMMD1 expression difference in BTZ-NRs vs BTZ-Rs was
log (fold-change)= 151 (P = 1.3E-2) and in the DEX-NRs vs DEX-Rs was log (fold-change)= 77 (P = 4.4E-1). For CUL1, expression difference in
BTZ-NRs vs BTZ-Rs was log (fold-change)= 32 (P= 2.8E-4) and in DEX-NRs vs DEX-Rs the change was log (fold-change)=− 21 (P = 1.1E-1).
Probes used were SKP1-200711, 200718, 200719, 2007974; SKP2-203625, 203626, 210567; CULLIN-1-207614; COMMD1-226024; RBX1-218117; and
CKS1B-201897.
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variance to determine if between-condition variability was greater than
within-condition variability. Genes identiﬁed above with a nominal P-value
o0.05 were further reﬁned by applying a fold-change requirement to
identify genes with a signiﬁcant differential. Fold-change was deﬁned as
the difference in median expression.
Cell lines and reagents
MM cell lines RPMI8226 and MM1.S (National Cancer Institute, Bethesda,
MD, USA) and U266 cells (American Tissue Culture Collection, Manassas,
VA, USA) were cultured as described.39,40 PI-resistant cells were generated
as described.40–42 Hemagglutinin (HA)-tagged Cullin-1 was from Addgene
(Cambridge, MA, USA). Bone marrow (BM) aspirates were obtained from
patients’ Institutional Review Board approval. Mononuclear cells were
removed and malignant plasma cells (PCs) puriﬁed by microbead selection
(Miltenyi Biotec, San Diego, CA, USA). Antibodies were directed against p27
(Santa Cruz Biotechnology, Dallas, TX, USA), phospho-Thr187 p27, Cks1,
Skp1, Skp2, Commd1 and GFP (Abcam, Cambridge, MA, USA) and Cullin-1
and HA (Cell Signaling Technology, Danvers, MA, USA). Bands were
visualized using LiCoR (Littleton, CO, USA) IRDye goat anti-mouse or
donkey anti-rabbit antibodies.
Cell viability
Cells viability was determined using the XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-
Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) assay. Relative viability was
calculated based on that of untreated cells. Cells were stained with
annexin-V ﬂuorescein isothiocyanate (Thermo-Fisher, Waltham, MA, USA)
and analyzed on a BD-LSR-Fortessa ﬂow cytometer (BD Biosciences, San
Jose, CA, USA) to quantitate apoptotic cells.
In vivo murine model of MM
To evaluate the effect of DT204 in vivo, 5-week-old female athymic NCr
(nu/nu) mice were injected in the tail vein with 2 × 106 MM1.S-luciferase-
expressing cells according to the Institutional Review Board-approved
protocols. Mice were randomized to four groups (7 or 8/group) and
received intravenous injection of vehicle (phosphate-buffered saline in
10% dimethylsulfoxide); BTZ (0.5 mg/kg), DT204 (10 mg/kg) or DT204+BTZ
administered on days 1, 3, 5, 7 and 9. Mice were imaged by
bioluminescence imaging at days 0 and 14. Animal body weights were
measured every third day from start of treatment. Treatment effect on
overall survival (OS) was determined using Kaplan–Meier curves.
Mice were killed when tumors reached 2 cm3, became ulcerated or
elicited complications that limited mobility and feeding.
Statistical analysis
In vitro assays were performed in triplicate. Statistical signiﬁcance of
differences was determined using the Student’s t- and analysis of variance
tests with a minimal level of signiﬁcance of Po0.05. In vivo statistical tests
were performed using the two-tailed Student’s t-test. Median OS was
determined using the Kaplan–Meier method with 95% conﬁdence
intervals.43 Prism Version 6.0 software (GraphPad, San Diego, CA, USA)
was used for statistical analyses.
Drug synergy
The Compusyn software and program was used to determine the effect of
drug combinations and general dose effects and is based on the median-
effect principle and the Chou–Talalay Combination Index–Isobologram
Theorem.44 The Chou–Talalay method for drug combination is based on
the median-effect equation, derived from the mass-action law principle,
which provides the common link between single entity and multiple
entities, and ﬁrst-order and higher-order dynamics. The resulting
combination index (CI) theorem of Chou–Talalay offers quantitative
deﬁnition for additive effect (CI = 1), synergism (CIo1) and antagonism
(CI41) in drug combinations.
RESULTS
Expression of SCFSkp2 components correlates with MM patient
survival
The goal of the present study was to identify genes within the
Ub+proteasome system that were upregulated in tumor cells from
MM patients that did not respond to BTZ as these genes represent
potentially actionable therapeutic targets. We analyzed data sets
from patients enrolled in pharmacogenomic studies performed to
compare the efﬁcacy of BTZ with other anti-myeloma agents.
Prospectively collected BM-derived PCs were analyzed to identify
candidates that correlated with treatment outcome. To determine
whether expression of the SCFSkp2 components offered prognostic
beneﬁt, patients that received BTZ were stratiﬁed based upon
gene expression and progression-free survival (PFS) or OS. CUL1,
COMMD1, SKP2 and CKS1B expression above the median value was
associated with signiﬁcantly decreased PFS and OS (Figure 1a).
SKP2 and CKS1B expression also correlated with reduced OS in
patients treated with BTZ in the HOVON-65/GMMG-HD4 trial
(Figure 1b). In trial 039, patients received treatment with either
BTZ or dexamethasone. As CUL1, SKP2, COMMD1 and CKS1B
expression negatively correlated with PFS and OS, we investigated
whether the expression of these genes also correlated with
treatment response (Figure 1c). The results indicated that the
expression of COMMD1 and CUL1 was negatively correlated with
the response to BTZ. However, the expression of these same
genes did not correlate with the response to dexamethasone
(Figure 1c). A heat map generated from DNA microarray data also
indicated that the expression of CUL, COMMD1 and SKP2 was
None
Bortezomib, 5nM
Bortezomib, 10nM
Carfilzomib, 5nM
Carfilzomib, 10nM
Ixazomib, 5nM 
Ixazomib, 10nM
Lenalidomide, 10nM
Treatment
Figure 2. CUL1 knockdown sensitizes BTZ-resistant cells to proteasome inhibition. Drug-sensitive or -resistant cells were transfected with
control shRNA or shRNA to speciﬁcally knockdown CUL1, COMMD1 or SKP2. Transfectants were then treated as indicated and the number of
annexin-positive cells determined in triplicate.
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signiﬁcantly greater in tumor cells from BTZ-non-responders
compared with BTZ-responders (Supplementary Figure 1A). Genes
upregulated in BTZ-responders were rank-ordered to indicate that
COMMD1, CUL1 and SKP2 were among the most highly
upregulated (Supplementary Figure 1B). COMMD1, CUL1 and
SKP2 expression was then compared in PCs from healthy
individuals and monoclonal gammopathy of unknown signiﬁ-
cance patients with those of smoldering MM and MM patients
(Supplementary Figure 1C). COMMD1, CUL1 and SKP2 expression
was greater in smoldering MM and MM patients than in healthy
individuals and monoclonal gammopathy of unknown signiﬁ-
cance patients.
CUL1, COMMD1 or SKP2 knockdown sensitizes cells to proteasome
inhibitors
To demonstrate a role for CUL1, COMMD1 and SKP2 in BTZ-
induced cytotoxicity, parental (drug-sensitive) MM cells were
transfected with either control (scrambled) short hairpin RNA
(shRNA) or shRNA directed against CUL1, COMMD1 or SKP2. Target
knockdown was conﬁrmed by quantitative reverse transcription–
PCR and western blot (Supplementary Figures 2A and B). MM cells
were then treated with different PIs and the number of annexin-V-
positive cells was quantitated (Figure 2). The results indicated that
knockdown of CUL1, COMMD1 or SKP2 increased the number of
annexin-V-positive cells after PI treatment. For example, after
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Figure 3. Relative expression of SCFSkp2 components in BTZ-sensitive or -resistant cells. (a) Quantitative reverse transcription
(qRT–PCR) of SKP2, COMMD1 and CUL1 expression in RPMI8226 BTZ-sensitive (S) or -resistant (R) cells. Coding sequences (5′–3′) were
based on the NCBI AceView BLAST system. qRT–PCR primer sequences (5′–3′) were as follows: SKP2 forward-CAGGCCTAAGCTAAATCGAGAG,
SKP2 reverse-CTGGCAATGGTGGTGAAATG; CUL1 forward-CAGAGGAGGCAGAACTAGAAGA, CUL1 reverse-CGTGTTGTACTGAAGCAGGATAG; and
COMMD1 forward AGCCAGCTATATCCAGAGGT, COMMD1 reverse CATGAGGCTCTCACGGATT. Total RNA was isolated using the RNeasy mini kit
(Qiagen, Germantown, MD, USA). cDNA synthesis was performed using the SuperScript III ﬁrst-Strand Synthesis System. qRT–PCR was
performed using iTaq Universal Sybr Green Supermix (Bio-Rad, Hercules, CA, USA) in the CFX96 Real-Time PCR detection system (Bio-Rad).
Polymerase activation and DNA denaturation was performed at 95 °C for 30 s followed by 40 cycles of denaturation at 95 °C for 5 s, annealing
at 50 °C for 30 s, extension at 60 °C for 30 s and the melting curve analyzed at 65–95 °C. Calculations were performed using the 2−ΔΔCt method,
where ΔCt is the Ct value of GADPH subtracted from the Ct value of the gene of interest. ΔΔCt is the ΔCt value of the control subtracted from
the ΔCt value of the gene of interest. Error bars were determined based on triplicate SKP1 expression that was not signiﬁcantly different
in parental vs resistant samples. (b) Western blot of Cullin-1, Commd1 and Skp2 in parental and PI-resistant cells. Lysates were separated by
SDS–polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and probed using indicated antibodies. (c) Effect of shRNA
knockdown of CUL1, COMMD1 and SKP2 on generation of annexin-V-positive cells. shRNA in the pLKO.1-TCR cloning vector were transfected
into 293T packaging cells with each plasmid, packaging envelope and lipofectamine-2000. Viral supernatants were concentrated and
resuspended in phosphate-buffered saline at 1 × 109 infectious units per ml, and used to transduce cells then selected in puromycin. Cells
were treated as indicated and annexin-positive cells then quantitated in triplicate.
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knockdown of CUL1, COMMD1 or SKP2, BTZ treatment (10 nM)
yielded 38, 40 and 42% annexin-V-positive cells compared with
17% in controls. In contrast, treatment with lenalidomide did not
signiﬁcantly increase the number of annexin-V-positive cells in
cells after the knockdown of CUL1, COMMD1 or SKP2. A similar
effect of CUL1, COMMD1 and SKP2 knockdown on the cytotoxic
Immunoblot
Commd1
HA-Cul-1 transfectant
BTZ treatment 
HA-tag IP    
IgG (control) IP
HA-Cullin 1
Commd1
HA-Cullin 1
HA-Cul-1 transfectant
BTZ treatment 
HA-tag 
IgG (control) 
IP
IP Immunoblot
Figure 4. Commd1 and Cullin1 regulation of p27. (a) Western blot of p27 from lysates after transfection with scrambled, COMMD1 or CUL1
shRNA. Cell lysates were prepared as previously described, separated by SDS–polyacrylamide gel electrophoresis and probed with indicated
antibodies.40 (b) Association of Commd1 with HA-tagged Cullin-1. Western blot of HA immunoprecipitates from PI-sensitive or -resistant
RPMI826 or U266 cells transfected with a plasmid that expressed HA-CUL-1 after PI treatment. Lysates were immunoprecipitated with IgG as
controls (lanes 1 and 2).
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Figure 5. DT204 effect on SCFSkp2 and p27 levels. (a) Compounds were added at 10 or 50 μM for 24 h and green ﬂuorescence in cells
transfected with the green ﬂuorescent protein-p27-expressing vector was measured. (b) DT204 co-treatment with BTZ increases the amount
of annexin-V-positive cells. Annexin-V-positive cells were quantitated by ﬂow cytometry. BTZ treatment alone at indicated concentrations
produced a negligible amount of annexin-V-positive cells.
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effect of PIs was also observed with U266 cells (Supplementary
Figure 2C).
Knockdown of CUL1, COMMD1 and SKP2 overcomes
resistance to PIs
To further investigate the role of CUL1, COMMD1 and SKP2 in the
therapeutic response to PIs, RPMI and U266 cells were exposed to
increased concentrations of the PIs BTZ, carﬁlzomib or ixazomib to
generate models of PI resistance. Gene sequencing demonstrated
that the proteasome catalytic gene PSMB5 was not mutated in the
RPMI8226 and U266 cells generated with drug-resistance to BTZ,
carﬁlzomib or ixazomib (Supplementary Figure 7). Quantitative
reverse transcription–PCR indicated that CUL1, COMMD1 and SKP2
expression levels were greater in the RPMI8226 and U266 PI-
resistant cells compared with the parental cells (Figure 3a and
Supplementary Table 1). Western blots indicated that the protein
level of Cullin-1, Commd1 and Skp2 was increased in the PI-
resistant RPMI8226 and U266 cells (Figure 3b). The PI-resistant
RPMI8226 and U266 cells also exhibited increased proteasome
catalytic activity, consistent with prior related studies
(Supplementary Table 2). This is consistent with previous reports
supporting the notion that BTZ-resistant cells contain more
proteasomes and/or more proteasome activity.45–47 Also, DNA
sequencing indicated that PSMB5, the gene that encodes the
proteasome subunit responsible for chymotrypsin-like activity,
was not mutated in the RPMI8226 cells resistant to BTZ, ixazomib
or carﬁlzomib. Sequencing also revealed that PSMB5 was not
mutated in drug-sensitive or -resistant U266 cells. PI-resistant cells
were then transfected with shRNA to reduce CUL1, COMMD1 or
SKP2 levels that was conﬁrmed by quantitative reverse transcrip-
tion–PCR and western blot (Supplementary Figure 3). CUL1,
COMMD1 or SKP2 knockdown increased the sensitivity of
PI-resistant RPMI8826 (Figure 3c) and U266 (Supplementary
Figure 3) cells to BTZ, carﬁlzomib or ixazomib.
Physical association of Cul1 and Commd1
RPMI8226 and U266 cells were transfected with control shRNA
or shRNA directed against COMMD1 or CUL1. Transfectants were
probed by western blot to demonstrate that COMMD1 or CUL1
knockdown increased p27 levels (Figure 4a). Parental and PI-
resistant cells were then transfected with a plasmid that expressed
HA-tagged Cullin-1 and treated as indicated. Lysates were
prepared, immunoprecipitated using an HA-speciﬁc antibody
and probed by western blot. Results indicated that Commd1
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Figure 6. DT204 combined with PIs overcomes PI resistance. BTZ-, CFZ- or IXZ-resistant cells were treated with DT204 alone or combined with
other agents as indicated, and the number of annexin-V-positive cells determined. Assays were performed in triplicate. Error bars represent
the s.d.
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was associated with HA-Cullin-1 in RPMI8226 and U266 cells, and
that the association was increased after BTZ treatment in both
parental and PI-resistant cells (Figure 4b).
Identiﬁcation of a novel SCFSkp2 inhibitor
SCFSkp2 inhibitors offer an attractive approach to pharmacologi-
cally target the Ub+proteasome system with more speciﬁcity than
currently available with PIs.42,48,49 On the basis of structural
features of Skp2, as well as those of known Skp2 inhibitors, we
performed virtual and computational screening to identify a panel
of novel compounds as potential SCFSkp2 inhibitors. RPMI8226
cells were transfected with pBABE-MN-IRES-E-GFP-p27, a plasmid
that expressed green ﬂuorescent protein-tagged p27 to assess the
effect of these compounds on p27 stability (Supplementary
Figure 4A). Compounds were incubated with the transfected cells
to identify those that increased green ﬂuorescence as a read-out
of p27 stability (Figure 5a). DT204 signiﬁcantly increased cellular
ﬂuorescence to a level greater than that observed with known
Skp2 inhibitors. Western blotting indicated that DT204 also
increased p27 levels in cell lysates (Supplementary Figures 4B
and C). In contrast to BTZ or carﬁlzomib, DT204 treatment did not
increase the level of p53. DT204 co-treatment with BTZ enhanced
the generation of annexin-V-positive cells compared with BTZ
alone in a number of different MM cell lines (Figure 5b). The
Chou–Talaly theorem and Compusyn software were used to
detect potential synergy between DT204 and BTZ. The CI values
for DT204 combined with BTZ at 1 nM were 0.7, 0.8 and 0.7 for
RPMI8226, U266 and MM1.S, respectively, to indicate formal
synergy when tested within the three different MM cell lines.
DT204 co-treatment with BTZ overcomes drug resistance
DT204 co-treatment induced apoptosis in cells resistant to the
proteasome inhibitors BTZ, carﬁlzomib or ixazomib (Figure 6). CI
values for the combination of DT204 and BTZ to treat BTZ-R, CFZ-R
an IXZ-R cells were o1, consistent with formal synergy. We
observed cross-sensitization, that is, DT204 sensitized BTZ-R cells
to not only BTZ but also CFZ and IXZ.
DT204 co-treatment with BTZ reduces MM patient PC growth and
colony formation in the presence of BMSCs
CD138+ PCs were isolated from MM patient BM and treated with
DT204, BTZ or both (Figure 7a). DT204 co-treatment with BTZ
synergistically reduced the viability of MM patient CD138+ PCs.
Patient PCs were then cultured alone or co-cultured with BMSCs
and treated with DT204, BTZ or both. The number of colonies
formed by patient PCs was then measured to indicate that DT204
co-treatment with BTZ reduced the number of colonies formed
after co-culture with BMSCs (Figure 7b).
DT204+BTZ triggers synergistic inhibition of MM xenograft growth
in vivo
We determined the in vivo efﬁcacy of DT204 in combination with
BTZ using bioluminescent MM cells injected through the tail vein
into murine models. Mice treated with DT204, BTZ or DT204+BTZ
showed a statistically signiﬁcant delay in tumor growth compared
with vehicle-treated mice (Figure 8a). DT204 was well-tolerated
and did not provoke overt dermatologic, musculoskeletal,
neurologic or body weight changes (Figure 8b). A statistically
signiﬁcant prolongation in median OS was observed in the DT204+
BTZ-treated group (34 days) compared with vehicle-treated
group (12 days), or in the group treated with DT204 BTZ alone
(24 and 26 days, Figure 8c). Western blot of tumor collected
from mice following treatment with DT204 or DT204+BTZ
showed a greater accumulation of p27 compared with the
other treatment groups (Figure 4d). The results suggest that
synergistic activity observed at the cellular level with DT204 in
combination with BTZ translates to in vivo efﬁcacy.
DISCUSSION
There remains an urgent and unmet need to deﬁne the molecular
mechanisms of BTZ resistance in order to enhance the use of
existing treatments and design more effective single-agent and
combination therapies. In the current study, we used a biologically
supervised approach that identiﬁed SCFSkp2 components as
molecular classiﬁers expressed at greater levels in tumors from
MM patients that did not respond to BTZ. Expression of COMMD1,
CUL1, SKP2 and CKS1B in tumors from relapsed/refractory patients
was also negatively correlated with PFS and OS. The same genes
were not signiﬁcantly upregulated in patients that failed to
respond to other anti-myeloma therapies and may therefore serve
as classiﬁers to stratify BTZ-based therapy.39 Cell-based assays
demonstrated that shRNA-mediated knockdown of COMMD1,
CUL1 or SKP2 enhanced the sensitivity of MM cells to BTZ and
synergistically enhanced the effect of BTZ. Furthermore, SCFSkp2
has previously been associated with tumor progression and drug
resistance,21,25–27 to suggest that SCFSkp2 inhibitors may restore
drug sensitivity to overcome BTZ resistance.
We identiﬁed a novel compound that inhibited SCFSkp2-
mediated degradation of p27 and enhanced the anti-myeloma
effect of BTZ in MM cell lines and patient samples. DT204
stabilized p27, reduced myeloma viability, synergistically
enhanced the anti-myeloma effect of BTZ and prevented Skp2
incorporation into the SCFSkp2 complex. DT204 was not toxic to
inactive or phytohemagglutinin-activated peripheral blood mono-
nuclear cells and promoted cell cycle arrest (Supplementary
Figure 4). Genetic knockout of SKP2 similarly promoted cell cycle
arrest and DT204 phenocopied the effect of SKP2 deﬁciency on
Patient #1
Patient #2
Patient #3
Patient #4
C
el
l V
ia
bi
lit
y,
 %
C
ol
on
ie
s 
fo
rm
ed
, t
ot
al
DT204, uM 0 0 10 10
BTZ, nM 0 3 0 3
DT204, uM 0 10 0 10 0 10 0 10 0 10 0 10
BTZ, nM 0 0 5 5 0 0 5 5 0 0 5 5
Figure 7. DT204 effect on MM patient PC viability and colony
formation. (a) DT204 effect alone or combined with BTZ was
determined using patient CD138+ cells. (b) Effect of BTZ and DT204
on colony formation from patient CD138+ cells cultured alone or
with stromal cells. CD138+ cells were labeled with carboxyﬂuor-
escein succinimidyl ester, co-cultured with HS.5 cells, treated as
indicated and green colonies counted.
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cell cycle arrest (Supplementary Figure 5). DT204 also displayed
p27-independent effects as observed by the effect on the viability
of cells transfected with a phospho-deﬁcient (T187A) p27 mutant
(Supplementary Figure 6). Finally, we observed that DT204
enhanced the effect of BTZ in a xenograft model of myeloma.
The marked antitumor activity of this combination, coupled with
the lack of its effect on peripheral blood mononuclear cells,
suggests a favorable therapeutic index.
The present studies link individual components of the SCFSkp2
complex to BTZ resistance and form the genetic basis to
prospectively deﬁne those patients that should beneﬁt from BTZ
therapy. The ﬁndings provide the rationale for the advancement
of genomic biomarker-based evaluation of patients for whom BTZ
is being considered. These studies also provide proof of concept
to target SCFSkp2 as a strategy to overcome therapeutic resistance
and provide the rationale for the development of novel drug
combinations to enhance the efﬁcacy of BTZ-based therapies in
MM. In summary, we demonstrate that the SCFSkp2-p27 axis
represents a major determinant in the ability of BTZ to induce
apoptosis.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
JD is recipient of the UC Hematology and Oncology Translational Studies Award and
a mentor in the Egyptian–US Joint Supervision Program. MAY is recipient of the
Egyptian Cultural and Educational Bureau Award in the Egyptian–US Joint
Supervision Program. SJ is recipient of the American Society of Hematology Wallace
H Coulter Award.
AUTHOR CONTRIBUTIONS
Agree with the manuscript’s results and conclusions: EM, SJ, MAY, NV, RK, AJ,
AB, PS, MD, FC, KCA and JD; designed the experiments: EM, MAY, SJ and JD;
analyzed the data: EM, SJ, MAY, NV, RK, AJ, AB, PS, MD, FC, KCA and JD; collected
data/did experiments for the study: EM, SJ, MAY, NV, RK, AJ, AB, MD, FC and JD;
contributed to writing of the paper: EM, MAY, NV, MD, KCA and JD; supervised
experiments: JD.
REFERENCES
1 Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.
2 Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological thera-
pies for the treatment of multiple myeloma. Best Pract Res Clin Haematol 2005; 18:
619–634.
3 Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C
et al. PANORAMA 2: panobinostat in combination with BTZ and
dexamethasone in patients with relapsed and BTZ-refractory myeloma. Blood
2013; 122: 2331–2337.
4 Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R et al. A small
molecule inhibitor of ubiquitin-speciﬁc protease-7 induces apoptosis in
multiple myeloma cells and overcomes BTZ resistance. Cancer Cell 2012; 22:
345–358.
5 Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y et al. Metabolic
signature identiﬁes novel targets for drug resistance in multiple myeloma.
Cancer Res 2015; 75: 2071–2082.
To
ta
l B
od
y 
W
ei
gh
t, 
g
Days from Start of Treatment
0 5 10 15 20 25 30 35
Vehicle
BTZ
DT204
BTZ+DT204
24
22
20
18
Days from Start of Treatment
0 5 10 15 20 25 30 35
p27
Histone 
Su
rv
iv
al
, %
Vehicle
BTZ
DT204
BTZ+DT204
100
80
60
40
20
0
BTZ  
DT204
- - + +
- + - +
Figure 8. DT204+BTZ triggers synergistic inhibition of MM xenograft growth in vivo. (a) Representative bioluminescence imaging of mice from
each treatment group at day 18 after treatment initiation. (b) Animal body weight after treatment with vehicle, DT204, BTZ or DT204+BTZ
combination. (c) Kaplan–Meier survival curve comparison of nude mice after subcutaneous injection of myeloma cells treated with vehicle,
DT204, BTZ or DT204+BTZ. (d) Western blot of p27 from tumor tissue of mice treated with vehicle, BTZ, DT204 or both.
SCFSkp2 inhibition overcomes BTZ resistance
E Malek et al
652
Leukemia (2017) 645 – 653
6 Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al.
Heterogeneity of genomic evolution and mutational proﬁles in multiple myeloma.
Nat Commun 2014; 5: 2997.
7 Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma.
Nat Rev Cancer 2012; 12: 335–348.
8 Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC et al. Intraclonal
heterogeneity and distinct molecular mechanisms characterize the development
of t(4,14) and t(11;14) myeloma. Blood 2012; 120: 1077–1086.
9 Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al.
Widespread genetic heterogeneity in multiple myeloma: implications for targeted
therapy. Cancer Cell 2014; 25: 91–101.
10 Deshaies RJ, Joazeiro CAP. RING domain E3 ubiquitin ligases. Annu Rev Biochem
2009; 78: 399–434.
11 Emanuele MJ, Elia AEH, Xu Q, Thoma CR, Izhar L, Leng Y et al. Global identiﬁcation
of modular cullin-RING ligase substrates. Cell 2011; 147: 459–474.
12 Orlowski R. Why proteasome inhibitors cannot ERADicate multiple myeloma.
Cancer Cell 2013; 24: 275–277.
13 Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE.
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic protea-
some inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289–304.
14 Nakayama KI, Nakayama K. Ubiquitin-ligases: cell-cycle control and cancer.
Nat Rev Cancer 2009; 6: 269–281.
15 Jia L, Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug
Targets 2011; 11: 347–356.
16 Bennett E, Rush J, Gygi SP, Harper JW. Dynamics of Cullin-Ring ubiquitin
ligase network revealed by systematic quantitative proteomics. Cell 2010; 143:
951–965.
17 Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of
the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol
Chem 2003; 278: 25752–25757.
18 Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex
and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 1998;
95: 11324–11329.
19 Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW. F-box proteins are receptors
that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex.
Cell 2007; 91: 209–219.
20 Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and
beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438–449.
21 Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J et al. Skp2 is
oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98:
5043–5048.
22 Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z et al. The Skp2-SCF E3 ligase
regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.
Cell 2012; 149: 1098–1111.
23 Kipreos ET, Lander LE, Wing JP, He WW, Hedgecock EM. Cul-1 is required for
cell cycle exit in C. elegans and identiﬁes a novel gene family. Cell 1996; 85:
829–839.
24 Wang Y, Penfold S, Tang X, Hattori N, Riley P, Harper JW et al. Deletion of the Cul1
gene in mice causes arrest in early embryogenesis and accumulation of cyclin E.
Curr Biol 1999; 9: 1191–1194.
25 Chen G, Li G. Increased CUL1 expression promotes melanoma cell proliferation
through regulating p27 expression. Int J Oncol 2010; 37: 1339–1344.
26 Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y et al. Overexpression of Cullin1 is
associated with poor prognosis of patients with gastric cancer. Hum Pathol 2011;
42: 375–383.
27 Min KW, Kim DH, Do SI, Sohn JH, Chae SW, Pyo J et al. Diagnostic and prognostic
relevance of Cullin1 expression in invasive ductal carcinoma of the breast. J Clin
Pathol 2012; 65: 896–901.
28 Wu S1, Zhu W, Nhan T, Toth JI, Petroski MD, Wolf DA. CAND1 controls in vivo
dynamics of the cullin 1-RING ubiquitin ligase repertoire. Nat Commun 2013; 4: 1642.
29 Mao X, Gluck N, Li H, Chen B, Wallis M, Maine GN et al. Copper metabolism MURR1
domain containing 1 (COMMD1) regulates Cullin-RING ligases by preventing
Cullin-associated NEDD8-dissociated (CAND1) binding. J Biol Chem 2011; 286:
32355–32365.
30 Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H. Deregulation of
COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.
Plos One 2014; 9: e91031.
31 Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM et al. CKS1B, overexpressed
in aggressive disease, regulates multiple myeloma growth and survival through
SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007; 109:
4995–5001.
32 Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT et al. Intracellular NAD
(+) depletion enhances BTZ-induced anti-myeloma activity. Blood 2013; 122:
1243–1255.
33 Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression
proﬁling and correlation with outcome in clinical trials of the proteasome inhi-
bitor BTZ. Blood 2007; 109: 3177–3188.
34 Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene
expression proﬁling of multiple myeloma, monoclonal gammopathy of unde-
termined signiﬁcance and normal bone marrow plasma cells. Blood 2002; 99:
1745–1757.
35 Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A et al. Gene expression
proﬁling for molecular classiﬁcation of multiple myeloma in newly diagnosed
patients. Blood 2010; 116: 2543–2553.
36 Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al.
A phase 2 study of BTZ in relapsed, refractory myeloma. N Engl J Med 2003; 348:
2609–2617.
37 Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase
2 study of two doses of BTZ in relapsed or refractory myeloma.
Br J Haematol 2004; 127: 165–172.
38 Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a phase 3
trial in relapsed multiple myeloma: ﬁnal time-to-event results of the APEX trial.
Blood 2007; 110: 3557–3560.
39 Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H
et al. Bortezomib induction and maintenance treatment in patients with newly
diagnosed multiple myeloma: results of the randomized phase III HOVON-65/
GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946–2955.
40 Jagannathan S, Vad N, Vallabhapurapu Su, Anderson KC, Driscoll JJ. MiR-29b
replacement inhibits proteasomes and disrupts aggresome+ autophagosome
formation to enhance the anti-myeloma beneﬁt of BTZ. Leukemia 2014; 29:
727–738.
41 Jagannathan S, Abdel Malek M, Malek E, Vad N, Anderson KC, Driscoll JJ.
Pharmacologic screens reveal metformin that suppresses GRP78-dependent
autophagy to enhance the anti-myeloma effect of BTZ. Leukemia 2015; 29:
2184–2191.
42 Wu L, Grigoryan AV, Li Y, Hao B, Pagano M, Cardozo TJ. Speciﬁc small molecule
inhibitors of Skp2-mediated p27 degradation. Chem Biol 2012; 19: 1515–1524.
43 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.
J Amer Statist Assn 1958; 53: 457–481.
44 Chou TC. Drug combination studies and their synergy quantiﬁcation using the
Chou-Talalay method. Cancer Res 2010; 70: 440–446.
45 Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL et al.
Molecular mechanisms of BTZ resistant adenocarcinoma cells. Plos One 2011; 6:
e27996.
46 Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM
et al. Bortezomib resistance in mantle cell lymphoma is associated with
plasmacytic differentiation. Blood 2011; 117: 542–552.
47 Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B
et al. Differential cellular and molecular effects of BTZ, a proteasome inhibitor, in
human breast cancer cells. Mol Cancer Ther 2006; 5: 665–675.
48 Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A et al. Pharmacological inacti-
vation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer
progression. Cell 2013; 154: 556–568.
49 Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D et al. Targeting
the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest
and activation of autophagy. Blood 2008; 111: 4690–4699.
This work is licensed under a Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 International License. The images or
other third party material in this article are included in the article’s Creative Commons
license, unless indicatedotherwise in the credit line; if thematerial is not included under
the Creative Commons license, users will need to obtain permission from the license
holder to reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)
SCFSkp2 inhibition overcomes BTZ resistance
E Malek et al
653
Leukemia (2017) 645 – 653
